The future of nitrosamine analysis and regulation is focused on addressing contamination in pharmaceuticals, driven by the problems identified in sartans. Experts emphasize the need for greater regulatory harmonization, advanced analytical techniques like LC-MS and HRMS, and prevention strategies to reduce nitrosamine formation. Collaboration among regulatory agencies and the industry is crucial to understanding nitrosamines' toxicological profiles. Resources from organizations like USP are vital, offering standards and a knowledge-sharing community to enhance control measures.
